



International  
Federation of  
Pharmaceutical  
Manufacturers &  
Associations

Fédération  
Internationale de  
l'Industrie du  
Médicament

Federación  
Internacional de la  
Industria del  
Medicamento



## News Release

### IFPMA salutes Québec's New Biopharmaceutical Strategy

Geneva, 9 October 2009 – The International Federation of Pharmaceuticals Manufacturers & Associations (IFPMA) notes with approval Québec's new Biopharmaceutical Strategy and salutes the provincial government's support for the biopharmaceutical industry, and its recognition of the important role that the sector plays, both as an economic driver and as a provider of life-saving medicines and vaccines.

On 8 October, the government of Québec unveiled a comprehensive Biopharmaceutical Strategy, which acknowledges the research-based pharmaceutical industry's strategic contribution to the province's economy and the inherent value of innovative medicines - both in terms of health outcomes and wealth creation.

The Strategy is specifically designed to initiate a permanent high-level dialog between government and industry, to create a more competitive and attractive business environment in Québec, engage the federal government on issues of data protection and intellectual property rights, generate funding for promising biotech startups, increase the Industry's capacity to attract foreign scientists and experts, and maximize the commercial potential of public biopharmaceutical research.

The IFPMA's Acting Director General, Mr. Michael D. Boyd, deems this governmental initiative to be a strong example of how bold policy decisions can ensure that the research-based pharmaceutical industry can play a leading role in improving access to innovative medicines and health care systems across the world.

**(ends)**

**About the IFPMA:**

The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise 27 leading international companies and 44 national and regional industry associations covering developed and developing countries. The industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, heart disease, HIV/AIDS and malaria. The IFPMA Clinical Trials Portal ([www.ifpma.org/ClinicalTrials](http://www.ifpma.org/ClinicalTrials)), the IFPMA's Ethical Promotion online resource ([www.ifpma.org/EthicalPromotion/](http://www.ifpma.org/EthicalPromotion/)) and its Developing World Health Partnerships information ([www.ifpma.org/HealthPartnerships](http://www.ifpma.org/HealthPartnerships)) help make the industry's activities more transparent. The IFPMA strengthens patient safety by improving risk assessment of medicines and combating their counterfeiting. It also provides the secretariat for the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

**For further information, please contact:**

Guy Willis  
Director of Communications  
E-mail: [g.willis@ifpma.org](mailto:g.willis@ifpma.org)  
Tel: +41 22 338 32 00  
Fax: +41 22 338 32 99  
Web: [www.ifpma.org](http://www.ifpma.org)